GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Antibody
Comment: Fianlimab (R3767; REGN3767) is a monoclonal antibody that targets the inhibitory immune checkpoint co-receptor lymphocyte activation gene-3 protein (LAG3; CD223) on tumour infiltrating lymphocytes [1]. It was proposed for immunotherapeutic antineoplastic activity.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Burova E, Hermann A, Dai J, Ullman E, Halasz G, Potocky T, Hong S, Liu M, Allbritton O, Woodruff A et al.. (2019)
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol Cancer Ther, 18 (11): 2051-2062. [PMID:31395688] |
